|
Post by joeypotsandpans on Aug 8, 2019 9:16:07 GMT -5
After hearing the good earnings call yesterday, I thought this stock is "not a sinking boat ..... and not a rocket ship". What should the shorts do now to make money off this very undervalued stock? 911k shares traded in first 28 min of trading.
|
|
|
Post by wgreystone on Aug 8, 2019 9:21:43 GMT -5
When u refinance ur mortgage to pay off ur old loan, it does not make ur house more valuable. Besides that, what else is new in the CC?
|
|
|
Post by alethea on Aug 8, 2019 9:24:01 GMT -5
After hearing the good earnings call yesterday, I thought this stock is "not a sinking boat ..... and not a rocket ship". What should the shorts do now to make money off this very undervalued stock? 911k shares traded in first 28 min of trading. I don't think the shorts stand to make a lot of additional profit by shorting from this point forward. They likely made a couple of billion, no exaggeration, since shorting MNKD down since its partnership with Sanofi in 2015. Now it's all about constraining and restricting the growth of Afrezza and harming MNKD by denying them capital via equity raises. Something they have done with a contract killer's effectiveness for years Look at today already. An entire day's volume in the first half hour following a very good conference call with lots of positives. And oh my, BIG SURPRISE. They have walked the price to 1.08. Doesn't that seem a bit strange? It is pure, simple manipulation. They will bore shareholders to death until they lose interest. I just bought again between the bid and ask of 1.08 and 1.09. MNKD has enough cash to survive for a year or more. Once again we are forced to wait for positive events like cash from UTHR and overseas progress, studies, label improvement and such to spur positive momentum. Wall Street, likely incentivised and funded by big Pharma can easily COMPLETELY control and manipulate MNKD's stock price. They have been wildly successful at doing so for years.
|
|
|
Post by awesomo on Aug 8, 2019 9:25:12 GMT -5
When u refinance ur mortgage to pay off ur old loan, it does not make ur house more valuable. Besides that, what else is new in the CC? You're right, but it does take foreclosure, getting in bed with loan sharks, etc. off the table for now. Of course, they still need to execute the actual business model, which has been sorely lacking so far.
|
|
|
Post by wgreystone on Aug 8, 2019 9:34:06 GMT -5
We have a FDA approved drug with addressable market of multi billion dollars. The CEO should focus on telling us how to sell the drug . Leave the refinancing pride to the CFO.
|
|
|
Post by wgreystone on Aug 8, 2019 9:48:25 GMT -5
TNDM just reported 174% revenue increase last quarter. It was once a $2 stock price company as well. Maybe MC should pay them a visit to learn how to sell a product in diabetic market.
|
|
|
Post by boytroy88 on Aug 8, 2019 9:59:57 GMT -5
After hearing the good earnings call yesterday, I thought this stock is "not a sinking boat ..... and not a rocket ship". What should the shorts do now to make money off this very undervalued stock? 911k shares traded in first 28 min of trading. I don't think the shorts stand to make a lot of additional profit by shorting from this point forward. They likely made a couple of billion, no exaggeration, since shorting MNKD down since its partnership with Sanofi in 2015. Now it's all about constraining and restricting the growth of Afrezza and harming MNKD by denying them capital via equity raises. Something they have done with a contract killer's effectiveness for years Look at today already. An entire day's volume in the first half hour following a very good conference call with lots of positives. And oh my, BIG SURPRISE. They have walked the price to 1.08. Doesn't that seem a bit strange? It is pure, simple manipulation. They will bore shareholders to death until they lose interest. I just bought again between the bid and ask of 1.08 and 1.09. MNKD has enough cash to survive for a year or more. Once again we are forced to wait for positive events like cash from UTHR and overseas progress, studies, label improvement and such to spur positive momentum. Wall Street, likely incentivised and funded by big Pharma can easily COMPLETELY control and manipulate MNKD's stock price. They have been wildly successful at doing so for years. I got antsy and bought more at $1.09 too... Should've waited a bit and could've gotten it at $1.07 😜. That said I had an inkling from previous experience that the SP would dip. Still think it might dip more but it's looking like $1.07 could be the bottom for today. We'll see. Hope I didn't jump in too early... Never amazes me what the shorts can do to this stock.
|
|
|
Post by shawnonafrezza on Aug 8, 2019 10:01:31 GMT -5
TNDM just reported 174% revenue increase last quarter. It was once a $2 stock price company as well. Maybe MC should pay them a visit to learn how to sell a product in diabetic market. Basal-IQ & the X2 were announced officially in June of 2018 and the stock started coming out of the $2 range in March of that year when people were anticipating it. So what did Tandem do? A revolutionary product (that people already knew how to use) with a partnership (Dexcom) to bring in more users with. Mannkind is in a similar place but the difference to me is the X2 sold itself; people were so happy to be able to dump Medtronic pumps.
|
|
|
Post by prcgorman2 on Aug 8, 2019 10:06:46 GMT -5
TNDM just reported 174% revenue increase last quarter. It was once a $2 stock price company as well. Maybe MC should pay them a visit to learn how to sell a product in diabetic market. This reminds me of an acerbic comment I might have made in the past.
Before you and others make a similar post, I highly recommend reading Stevil's and Matt's recent posts within the last week about the realities of convincing FDA, insurers, and prescribers to put Afrezza on par with less effective but cheaper alternatives. Their ain't no silver bullet, VDEX included.
|
|
|
Post by sweedee79 on Aug 8, 2019 10:51:11 GMT -5
TNDM just reported 174% revenue increase last quarter. It was once a $2 stock price company as well. Maybe MC should pay them a visit to learn how to sell a product in diabetic market. I'm kinda feeling same as you.. I'm happy with the recap... But now I want to see something happen.. I'm happy with the billboards, but we still have problems with docs not wanting to prescribe.. or not prescribing correctly.. and retention problems.. it's a big problem.. And I'd like to see something pull this pps up.. we are lingering too close to 1$..Not sure what that is going to take but we need it.
|
|
|
Post by Thundersnow on Aug 8, 2019 12:30:03 GMT -5
TNDM just reported 174% revenue increase last quarter. It was once a $2 stock price company as well. Maybe MC should pay them a visit to learn how to sell a product in diabetic market. I'm kinda feeling same as you.. I'm happy with the recap... But now I want to see something happen.. I'm happy with the billboards, but we still have problems with docs not wanting to prescribe.. or not prescribing correctly.. and retention problems.. it's a big problem.. And I'd like to see something pull this pps up.. we are lingering too close to 1$..Not sure what that is going to take but we need it. Well like Mike said at the end of the CC. They need to meet with potential investors and get their story out. Investor Relations will have to line up the conferences and Mike & Co. need to hit the road and get the word out. With revenues rising >50% that's a good story to tell but Mike had to clean up the house. The house is done and now they can tell a great story. it will take time but now is the time to add to your position. Debt is not due until 2024 (5 YEARS FROM NOW) and new money is coming in. That's what Tandem did and we see their stock appreciation.
|
|
|
Post by prcgorman2 on Aug 8, 2019 12:31:36 GMT -5
I'll repeat my admonition to read, if you haven't already, the following: Stevil in WTF on 8/5 - mnkd.proboards.com/post/185543/thread Matt in WTF on 8/6 - mnkd.proboards.com/post/185570/threadI am convinced we longs need to stop holding on to the idea of simple, cheap, quick hitter actions. e.g., VDEX except that VDEX buildout would be slow (18 months minimum) even if MNKD partnered with them. It is unreasonable to expect that approaches that are simple, naive, or sophomoric, will make a material improvement in the stock price. What is going to move the stock price is executing on the plan Dr. Castagna and team have laid out and are operating against, BUT that doesn't mean near-term big improvements in stock price. I don't want to list out all of the reasons for my conviction because than I'll read like agedhippie and folks of questionable allegiance to Mannkind and the long thesis. I will say that the turning point for my view going from "if only we do X" to "this is going to take a relatively long time" was the failure of the TV DTC to move the needle in any measurable way. But I am not dismayed. I like buying stock at a very cheap price, especially when my expectations for gain are improving substantially. Say what you will about yesterday's earnings report, there has been measurable and substantive progress since 2017 under Dr. Castagna's leadership. The argument for material double-digit royalties on an inhalable PAH product marketed by UTHR is persuasive. UTHR is not RLS and $50M in milestone payments is not chump change. I believe Stevil and Matt are correct. Afrezza will be successful 1 of 2 ways; viral based on testimony (enhanced by CGM data), or traditional large-scale clinical trials proving superiority, changing the label and the minds of FDA, insurers, and most importantly, prescribers. This is what Sanofi, Eli Lilly, or Novo Nordisk do. Both, or hybrid is possible. Long-shot Hail Mary actions are just that. Like it or not, it is reality.
|
|
|
Post by Thundersnow on Aug 8, 2019 12:32:03 GMT -5
TNDM just reported 174% revenue increase last quarter. It was once a $2 stock price company as well. Maybe MC should pay them a visit to learn how to sell a product in diabetic market. Basal-IQ & the X2 were announced officially in June of 2018 and the stock started coming out of the $2 range in March of that year when people were anticipating it. So what did Tandem do? A revolutionary product (that people already knew how to use) with a partnership (Dexcom) to bring in more users with. Mannkind is in a similar place but the difference to me is the X2 sold itself; people were so happy to be able to dump Medtronic pumps. The stock will continue to DIP and there will be BEAR RAIDS. Just set limit orders and hopefully it will get executed. The street wants to scare you out of your shares. That's the time to POUNCE and BUY.
|
|
|
Post by Thundersnow on Aug 8, 2019 12:34:34 GMT -5
Spencer will detail all of that out in the next 24 hours for us. It's not solely on the shoulders of scripts. Having R&D cash from UTHR helps.
|
|
|
Post by Thundersnow on Aug 8, 2019 12:36:36 GMT -5
Paid off means paid off. Not sure how mnkd would be required to pay any future milestone payments. If DF is out of the picture they are completely out of the picture. Deerfield is out of the picture. I believe they sold off their interest in the Sales Milestones to a third party.
|
|